Clinical and Economic Outcomes Among Patients With Diabetes Mellitus Initiating Insulin Glargine Pen Versus Vial

References

• . American Diabetes Association. Standards of medical care in diabetes— 2012. Diabetes Care. 2012;35( suppl 1):S11–S63
   PubMed Web of Science ®Google Scholar
• . Brown JB, Nichols GA, Glauber HS. Case-control study of 10 years of comprehensive diabetes care. West J Med. 2000;172(2):85–90
   PubMedGoogle Scholar
• . CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287(19):2542–2551
   PubMed Web of Science ®Google Scholar
• . Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999–2004. Curr Med Res Opin. 2009;25(7):1605–1613
   PubMed Web of Science ®Google Scholar
• . Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81–86
   PubMed Web of Science ®Google Scholar
• . Campbell RK. Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing insulin-based therapy. Am J Manag Care. 2012;18( 3 suppl):S55–S61
   PubMedGoogle Scholar
• . Kapitza C, Fein S, Heinemann L, Schleusener D, Levesque S, Strange P. Basal-prandial insulin delivery in type 2 diabetes mellitus via the V-Go: a novel continuous subcutaneous infusion device. J Diabetes Sci Technol. 2008;2(1):40–46
   PubMedGoogle Scholar
• . Petrak F, Stridde E, Leverkus F, Crispin AA, Forst T, Pfützner A. Development and validation of a new measure to evaluate psychological resistance to insulin treatment. Diabetes Care. 2007;30(9):2199–2204
   PubMed Web of Science ®Google Scholar
• . Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27( suppl 3):13–20
   PubMed Web of Science ®Google Scholar
• . Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011;17(6):845–852
   PubMed Web of Science ®Google Scholar
• . Toscano D, Brice J, Alfaro C. Usage and perceptions of pen injectors for diabetes management: a survey of type 2 diabetes patients in the United States. J Diabetes Sci Technol. 2012;6(3):686–694
   PubMedGoogle Scholar
• . Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009;11(8):529–538
   PubMed Web of Science ®Google Scholar
• . Asakura T. Comparison of clinically relevant technical attributes of five insulin injection pens. J Diabetes Sci Technol. 2011;5(5):1203–1209
   PubMedGoogle Scholar
• . Xie L, Wei W, Pan C, Du J, Baser O. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther. 2011;28(11):1000–1011
   PubMed Web of Science ®Google Scholar
• . Lee LJ, Li Q, Reynolds MW, Engelman W. Trend analyses of insulin delivery systems in the United States. J Diabetes Sci Technol. 2011;5(5):1116–1123
   PubMedGoogle Scholar
• . Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther. 2010;27(2):94–104
   PubMed Web of Science ®Google Scholar
• . McAdam-Marx C, Yu J, Bouchard J, Aagren M, Brixner DI. Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Cur Med Res Opin. 2010;26(1):191–201
   PubMed Web of Science ®Google Scholar
• . Quan H, Sundararajan V, Halfon P, . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139
   PubMed Web of Science ®Google Scholar
• . United States Department of Labor. Bureau of Labor Statistics. Consumer Price Index—All Urban Consumers: Medical Care, http://data.bls.gov/timeseries/CUUR0000SAM?output_view=pct_12mths. Accessed April 5, 2013
   Google Scholar
• . Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55
   Web of Science ®Google Scholar
• . D'Agostino R. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–2281
   PubMed Web of Science ®Google Scholar
• . Kurth T, Walker AM, Glynn RJ, . Results of multivariate logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006;163(3):262–270
   PubMed Web of Science ®Google Scholar
• . Buysman E, Conner C, Aagren M, Bouchard J, Liu F. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naive patients with type 2 diabetes. Curr Med Res Opin. 2011;27(9):1709–1717
   PubMed Web of Science ®Google Scholar
• . Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712–1725
   PubMed Web of Science ®Google Scholar
• . Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948–962
   PubMed Web of Science ®Google Scholar
• . Lee LJ, Li Q, Reynolds MW, Pawaskar MD, Corrigan SM. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. J Med Econ. 2011;14(1):75–86
   PubMedGoogle Scholar
• . Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12( suppl 1):S101–S108
   PubMed Web of Science ®Google Scholar
• . Lin J, Ling J, Wei W, Pan C. Outcomes of initiating insulin glargine therapy with disposable pen or vial among patients with type 2 diabetes in a U.S. managed care health plan. J Diabetes Sci Technol. 2012;6(2):A90–A91
   Google Scholar
• . Hirsch L, Gibney M, Berube J, Manocchio J. Impact of a modified needle tip geometry on penetration force as well as acceptability, preference, and perceived pain in subjects with diabetes. J Diabetes Sci Technol. 2012;6(2):328–335
   PubMedGoogle Scholar
• . Stockl K, Ory C, Vanderplas A, . An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin. 2007;23(1):133–146
   PubMed Web of Science ®Google Scholar
• . Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836–2848
   PubMed Web of Science ®Google Scholar
• . Asakura T, Seino H, Nakano R, . A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol Ther. 2009;11(10):657–661
   PubMed Web of Science ®Google Scholar
• . Pearson T. Practical aspects of insulin pen devices. J Diabetes Sci Technol. 2010;4(3):522–531
   PubMedGoogle Scholar
• . Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31(3):430–432
   PubMed Web of Science ®Google Scholar
• . Shaghouli AA, Shah BR. The prescription of insulin pen devices versus syringes for older people with diabetes. Diabetes Technol Ther. 2009;11(7):439–442
   PubMed Web of Science ®Google Scholar